5XE Stock Chart & Stats
€19.40
€0.40(1.72%)
At close: 4:00 PM EDT
€19.40
€0.40(1.72%)
Day’s Range― - ―
52-Week Range€7.90 - €24.00
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€1.82B
Enterprise Value€3.94K
Total Cash (Recent Filing)€93.47M
Total Debt (Recent Filing)€645.75M
Price to Earnings (P/E)23.4
Beta0.39
Next Earnings
Nov 05, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.32
Shares Outstanding95,046,400
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)4.88
Price to Sales (P/S)1.10
P/FCF Ratio28.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.20Price Target Upside24.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.95
Revenue Forecast (FY)€1.42B
Bulls Say, Bears Say
Bulls Say
Growth And Acquisition ExecutionStrong organic volume growth plus acquisitions performing above underwriting supports a larger operating platform. This can improve scale, diversify revenue sources and create durable earnings growth if integration benefits are captured.
Liquidity And Capital StructureThe unsecured financing and expanded liquidity improve funding flexibility for operations, integration and redevelopment. Longer maturities and lower average interest reduce refinancing pressure while management executes its growth strategy.
LTC Redevelopment PipelineRedevelopment expands modern long-term-care capacity and provides a multi-year avenue for growth in a structurally aging market. A visible project pipeline can support occupancy, care capacity and future operating earnings.
Bears Say
Leverage And Cash ConversionRenewed leverage and weak conversion of earnings into free cash flow constrain financial flexibility. These issues may limit reinvestment capacity and increase sensitivity to funding costs or operating disruptions over the next several quarters.
Home-health Margin PressureRapid expansion is currently absorbing technology and staffing costs while provincial rate timing remains uncertain. Unless volume growth eventually produces operating leverage, sustained investment and funding pressure could restrain segment profitability.
Integration Execution RiskThe enlarged platform requires prolonged regional cutovers and transitional services, creating execution complexity and recurring costs. Delays could defer targeted synergies, disrupt service delivery or reduce the earnings contribution of acquisitions.
Extendicare News
5XE FAQ
What was Extendicare’s price range in the past 12 months?
Extendicare lowest stock price was €7.90 and its highest was €24.00 in the past 12 months.
What is Extendicare’s market cap?
Extendicare’s market cap is €1.82B.
When is Extendicare’s upcoming earnings report date?
Extendicare’s upcoming earnings report date is Nov 05, 2026 which is in 66 days.
How were Extendicare’s earnings last quarter?
Extendicare released its earnings results on Aug 06, 2026. The company reported €0.199 earnings per share for the quarter, missing the consensus estimate of €0.246 by -€0.047.
Is Extendicare overvalued?
According to Wall Street analysts Extendicare’s price is currently Undervalued.
Does Extendicare pay dividends?
Extendicare does not currently pay dividends.
What is Extendicare’s EPS estimate?
Extendicare’s EPS estimate is 0.23.
How many shares outstanding does Extendicare have?
Extendicare has 95,046,400 shares outstanding.
What happened to Extendicare’s price movement after its last earnings report?
Extendicare reported an EPS of €0.199 in its last earnings report, missing expectations of €0.246. Following the earnings report the stock price went down -4.717%.
Which hedge fund is a major shareholder of Extendicare?
Currently, no hedge funds are holding shares in DE:5XE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Extendicare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€24.20 (24.75% Upside)
€24.20 (24.75% Upside)
Insider Transactions
Sold Shares
Worth C$65.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.44%
12-Months-Change
Fundamentals
Return on Equity
1.67%
Trailing 12-Months
Asset Growth
100.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Extendicare
Extendicare Inc. operates across Canada, delivering a wide array of vital care and support services specifically designed for the senior population through its various subsidiaries. The company's diverse service portfolio includes long-term care facilities, a range of retirement living options, and comprehensive home-based health services. These home health offerings span professional nursing care, various rehabilitative therapies (including occupational, physical, and speech therapy), and assistance with everyday activities. Additionally, Extendicare offers contract and consulting expertise to external entities. The organization oversees an extensive network consisting of 119 long-term care residences and retirement communities, alongside its dedicated home health care operations. These services are provided under prominent brand names such as Extendicare, Esprit Lifestyle Communities, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network. Founded in 1968, Extendicare Inc. is headquartered in Markham, Canada.
5XE Stock 12 Month Forecast
Average Price Target
€24.20
▲(24.75% Upside)